Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$47.33 USD
+1.41 (3.07%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $47.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PTGX 47.33 +1.41(3.07%)
Will PTGX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
4 Stocks to Buy for Attractive Earnings Acceleration
Other News for PTGX
Protagonist Therapeutics Board and Audit Committee Changes
Protagonist Therapeutics price target raised by $10 at H.C. Wainwright, here's why
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024
Interesting PTGX Put And Call Options For July 2025
Protagonist Therapeutics price target lowered to $43 from $45 at JMP Securities